Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
February 26 2021 - 8:45AM
Celsion Corporation (NASDAQ:
CLSN), a clinical-stage development company focused on
DNA-based immunotherapy and next-generation vaccines, today
announced that management will be holding one-on-one meetings with
investors during the Virtual 33rd Annual Roth Conference, being
held March 15 – 17, 2021. A webcast of Celsion’s presentation will
be pre-recorded and will be available on the Company’s website
during the week before the conference.
Institutional and other investors interested in
meeting with Celsion during the conference should contact their
Roth Capital Partners sales representative or LHA Investor
Relations. Conference information is available at
www.roth.com/oc2021virtual.
About Celsion
Corporation
Celsion is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative cancer treatments, including immunotherapies, DNA-based
therapies and directed chemotherapies through clinical trials and
eventual commercialization. The company’s product pipeline includes
GEN-1, a DNA-based immunotherapy for the localized treatment of
ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal
encapsulation of doxorubicin, is under investigator-sponsored
development for several cancer indications. Celsion also has two
feasibility stage platform technologies for the development of
novel nucleic acid-based immunotherapies and other anti-cancer DNA
or RNA therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit www.celsion.com.
Celsion Investor ContactJeffrey
W. ChurchExecutive Vice President and
CFO609-482-2455jchurch@celsion.com
LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024